Lineage Cell Therapeutics, Inc.

(NYSE: LCTX)

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

Contact Information

Website: www.lineagecell.com
Email: IR@lineagecell.com
Main Phone: +1 442 287-8990
Address: 2173 Salk Avenue
Address 2: Suite 200
State: CA
City / Town: Carlsbad
Country: US
Postal Code: 92008

Issuer Information

Exchange: AMX
CEO: Brian M. Culley
Employees: 55
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A